Dicerna Pharmaceuticals’ (DRNA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a report released on Friday morning, AnalystRatings.com reports. The brokerage currently has a $22.00 price objective on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a hold rating to a buy rating and set a $13.00 price objective for the company in a report on Tuesday, March 12th. BidaskClub raised shares of Dicerna Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, March 6th. Chardan Capital raised shares of Dicerna Pharmaceuticals from a neutral rating to a buy rating and set a $18.00 price objective for the company in a report on Tuesday, January 22nd. B. Riley increased their price objective on shares of Dicerna Pharmaceuticals from $21.00 to $24.00 and gave the company a buy rating in a report on Wednesday, March 13th. Finally, SunTrust Banks upped their target price on shares of Dicerna Pharmaceuticals to $26.00 and gave the company a buy rating in a research report on Wednesday, March 13th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $22.13.

DRNA opened at $13.32 on Friday. Dicerna Pharmaceuticals has a 52 week low of $9.31 and a 52 week high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Dicerna Pharmaceuticals had a negative net margin of 1,438.68% and a negative return on equity of 53.27%. The company had revenue of $1.54 million for the quarter, compared to the consensus estimate of $8.38 million. As a group, equities analysts forecast that Dicerna Pharmaceuticals will post -0.99 earnings per share for the current fiscal year.

In other news, insider James B. Weissman sold 15,000 shares of the company’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the sale, the insider now directly owns 39,480 shares in the company, valued at approximately $592,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 19.85% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers raised its position in shares of Dicerna Pharmaceuticals by 4.3% during the 1st quarter. Rhumbline Advisers now owns 70,078 shares of the biopharmaceutical company’s stock valued at $1,027,000 after buying an additional 2,886 shares in the last quarter. Quantamental Technologies LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter valued at about $26,000. SG Americas Securities LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter valued at about $569,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Dicerna Pharmaceuticals by 8.9% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,618 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 945 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter valued at about $4,501,000. Hedge funds and other institutional investors own 85.72% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Further Reading: Quiet Period Expirations

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.